Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-03-14 DOI:10.1002/cam4.70673

Zerubbabel K. Asfaw, Tirone Young, Cole Brown, Mehek Dehdia, Lily Huo, Kunal K. Sindhu, Stanislav Lazarev, Robert Samstein, Sheryl Green, Isabelle M. Germano

{"title":"Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades","authors":"Zerubbabel K. Asfaw, Tirone Young, Cole Brown, Mehek Dehdia, Lily Huo, Kunal K. Sindhu, Stanislav Lazarev, Robert Samstein, Sheryl Green, Isabelle M. Germano","doi":"10.1002/cam4.70673","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well-defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption and evolution for brain cancer and tumors globally.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic literature review of SRS-focused articles from 2000 to 2023 was conducted. Literature impact was evaluated using citation counts and relative citation ratio scores. Extracted data were dichotomized between US and international publications.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Out of 5424 articles eligible, 538 met inclusion criteria reporting on 120,756 patients treated with SRS for brain cancer and tumors since 2000. Over time, publication rates grew significantly (<i>p</i> = 0.0016), with 56% of principal investigators based in the United States. Clinical articles accounted for 87% of the publications, with the remainder focused on technological advances. Relative to international studies, US publications had larger median samples (74 vs. 58, <i>p</i> = 0.012), higher median citations (30 vs. 19, <i>p</i> < 0.0001) and higher relative citation ratio scores (1.67 vs. 1.2, <i>p</i> < 0.00001). Gamma Knife and LINAC had roughly equal representation in US and international publications. Neurosurgery specialists authored more Gamma Knife-based articles, and radiation oncology specialists authored more LINAC-based papers (<i>p</i> < 0.0001). The most treated tumors were metastases (58%), skull base tumors (35%), and gliomas (7%). Radiographic control was achieved in 82% of metastatic tumor cases, with a 12% median complication rate.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SRS has been widely adopted both nationally and globally and continues to be a growing field. This study corroborates the clinical efficacy of SRS and reinforces its critical role in the multidisciplinary treatment of patients with brain tumors and cancer.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70673","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70673","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well-defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption and evolution for brain cancer and tumors globally.

Methods

A systematic literature review of SRS-focused articles from 2000 to 2023 was conducted. Literature impact was evaluated using citation counts and relative citation ratio scores. Extracted data were dichotomized between US and international publications.

Results

Out of 5424 articles eligible, 538 met inclusion criteria reporting on 120,756 patients treated with SRS for brain cancer and tumors since 2000. Over time, publication rates grew significantly (p = 0.0016), with 56% of principal investigators based in the United States. Clinical articles accounted for 87% of the publications, with the remainder focused on technological advances. Relative to international studies, US publications had larger median samples (74 vs. 58, p = 0.012), higher median citations (30 vs. 19, p < 0.0001) and higher relative citation ratio scores (1.67 vs. 1.2, p < 0.00001). Gamma Knife and LINAC had roughly equal representation in US and international publications. Neurosurgery specialists authored more Gamma Knife-based articles, and radiation oncology specialists authored more LINAC-based papers (p < 0.0001). The most treated tumors were metastases (58%), skull base tumors (35%), and gliomas (7%). Radiographic control was achieved in 82% of metastatic tumor cases, with a 12% median complication rate.

Conclusions

SRS has been widely adopted both nationally and globally and continues to be a growing field. This study corroborates the clinical efficacy of SRS and reinforces its critical role in the multidisciplinary treatment of patients with brain tumors and cancer.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.